SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

PINOTTI, Mirko
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.531
EU - Europa 3.152
AS - Asia 2.235
OC - Oceania 13
SA - Sud America 9
AF - Africa 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 16.950
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.513
CN - Cina 1.243
IT - Italia 827
UA - Ucraina 715
DE - Germania 537
TR - Turchia 473
GB - Regno Unito 298
SG - Singapore 292
PL - Polonia 203
FI - Finlandia 172
SE - Svezia 165
BE - Belgio 64
ID - Indonesia 63
FR - Francia 39
VN - Vietnam 33
CZ - Repubblica Ceca 30
HK - Hong Kong 26
RU - Federazione Russa 25
IN - India 24
NL - Olanda 19
IR - Iran 17
JP - Giappone 16
CA - Canada 15
AU - Australia 11
KR - Corea 11
NO - Norvegia 11
RO - Romania 11
DK - Danimarca 10
BR - Brasile 8
CH - Svizzera 8
GE - Georgia 8
TW - Taiwan 8
IQ - Iraq 6
PT - Portogallo 6
AT - Austria 3
ES - Italia 3
EU - Europa 3
IE - Irlanda 3
IL - Israele 3
PK - Pakistan 3
KE - Kenya 2
MX - Messico 2
MY - Malesia 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
TH - Thailandia 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
BG - Bulgaria 1
BO - Bolivia 1
CR - Costa Rica 1
LU - Lussemburgo 1
MA - Marocco 1
MT - Malta 1
PH - Filippine 1
ZA - Sudafrica 1
Totale 16.950
Salva come PNG Salva come JPEG
Città #
Fairfield 1.429
Woodbridge 1.423
Chandler 991
Houston 915
Jacksonville 812
Ann Arbor 719
Ashburn 676
Seattle 598
Wilmington 555
Cambridge 474
Ferrara 336
Izmir 307
Nanjing 255
Princeton 231
Beijing 214
Warsaw 202
Singapore 166
New York 150
Boardman 149
Shanghai 140
San Diego 132
Milan 123
Dearborn 109
Bremen 105
Nanchang 83
Shenyang 71
Jakarta 61
Los Angeles 61
Falls Church 60
Brussels 57
Jiaxing 57
Redwood City 54
Tianjin 48
Hebei 45
Changsha 44
Jinan 42
San Mateo 37
Mountain View 35
Dong Ket 33
Kunming 30
Norwalk 30
Des Moines 28
Bologna 27
Guangzhou 27
London 27
Auburn Hills 24
Ningbo 24
Brno 23
Helsinki 22
Zhengzhou 20
Padova 18
Washington 18
Orange 17
Monmouth Junction 16
Indiana 14
Hong Kong 13
Toronto 13
Augusta 12
Düsseldorf 12
Hangzhou 12
Leawood 12
Taizhou 10
Ferrara di Monte Baldo 9
Florence 9
Hefei 9
Munich 9
Piemonte 9
Copenhagen 8
Naples 8
Oslo 8
Paris 8
Rome 8
Andover 7
Hounslow 7
Olomouc 7
Redmond 7
Verona 7
Addison 6
Chicago 6
Fuzhou 6
Rochester 6
Taipei 6
Baghdad 5
Lanzhou 5
Philadelphia 5
Santa Clara 5
Tokyo 5
Trieste 5
Alexandria 4
Amsterdam 4
Ardabil 4
Calvisano 4
Castagnole delle Lanze 4
Catania 4
Clifton 4
Fars 4
Haikou 4
Hyderabad 4
Kilburn 4
Louvain 4
Totale 12.676
Salva come PNG Salva come JPEG
Nome #
Exploring Splicing-Switching Molecules For Seckel Syndrome Therapy 180
An exon-specific U1snRNA induces a robust factor IX activity in mice expressing multiple human FIX splicing mutants 170
Regulation of a strong F9 cryptic 5'ss by intrinsic elements and by combination of tailored U1snRNAs with antisense oligonucleotides 167
Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency 159
Fo ATP synthase C subunit serum levels in patients with ST-segment Elevation Myocardial Infarction: Preliminary findings 156
Stimulation of P2 (P2X7) receptors in human dendritic cells induces the release of tissue factor-bearing microparticles. 149
An engineered tale-transcription factor rescues transcription of factor VII impaired by promoter mutations and enhances its endogenous expression in hepatocytes 146
Mcl-1 involvement in mitochondrial dynamics is associated with apoptotic cell death 145
Polymorphisms at LDLR locus may be associated with coronary artery disease through modulation of coagulation factor VIII activity and independently from lipid profile 141
Molecular Basis and Therapeutic Strategies to Rescue Factor IX Variants That Affect Splicing and Protein Function 141
The carboxyl-terminal region is NOT essential for secreted and functional levels of coagulation factor X 140
VITAMIN K-INDUCED MODIFICATION OF COAGULATION PHENOTYPE IN VKORC1 HOMOZYGOUS DEFICIENCY 137
Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca 2+ levels and tumor growth 137
Nuove strategie per la veicolazione di acidi nucleici: nanosistemi cationici a matrice lipidica 135
Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations 133
Transposon-mediated Generation of Cellular and Mouse Models of Splicing Mutations to Assess the Efficacy of snRNA-based Therapeutics 131
Chronic sleep deprivation markedly reduces coagulation factor VII expression 130
The dominant-negative von Willebrand factor gene deletion p.P1127-C1948delinsR: Molecular mechanism and modulation 125
Responsiveness of hemophilia B- causing non sense mutations to ribosome readthrough-inducing drugs strictly depends on the nucleotide and prrotein context 123
U1snRNA-mediated rescue of mRNA processing in severe factor VII deficiency 120
A frequent human coagulation Factor VII mutation (A294V, c152) in loop 140s affects the interaction with activators, tissue factor and substrates. 119
Factor XIII-A dynamics in acute myocardial infarction: a novel prognostic biomarker? 119
The carboxyl-terminal region is not essential for secreted and functional levels of coagulation factor X 118
Circadian rhythms in mouse blood coagulation 117
Activation of a cryptic splice site in a potentially lethal coagulation defect accounts for a functional protein variant 116
U1-snRNA-mediated rescue of mRNA processing in severe factor VII deficiency 116
Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency 115
Cationic lipid nanosystems as carriers for nucleic acids 115
Asymmetric processing of mutant factor X Arg386Cys reveals differences between intrinsic and extrinsic pathway activation 115
Effective hemostasis during minor surgery in a case of hereditary combined deficiency of vitamin K-dependent clotting factors 114
Major differences in bleeding symptoms between factor VII deficiency and hemophilia B 114
Temporal variations of coagulation factor VII activity in mice are influenced by lighting regime 113
An exon-specific U1 small nuclear RNA (snRNA) strategy to correct splicing defects 113
Influence of polymorphisms in the factor VII gene promoter on activated factor VII levels and on the risk of myocardial infarction in advanced coronary atherosclerosis 112
Membrane binding and anticoagulant properties of protein S natural variants 112
Molecular defects in CRM+ factor VII deficiencies: modelling of missense mutations in the catalytic domain of FVII 112
Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. 111
Variation of factor VII 140s and 170s loops in fishes: evolutionary aspects and comparison with mutations found in FVII deficiency 111
Ribosome readthrough accounts for secreted full-length factor IX in hemophilia B patients with nonsense mutations 111
Residual factor VII activity and different hemorrhagic phenotypes in CRM+ factor VII deficiencies (Gly331Ser and Gly283Ser) 110
Asymptomatic carriership of factor V Leiden and genotypes of the fibrinogen gene cluster 109
The chaperone-like sodium phenylbutyrate improves factor IX intracellular trafficking and activity impaired by the frequent p.R294Q mutation 109
Detection and characterization of polymorphic markers in the factor-VII gene. 108
Rescue of coagulation factor VII function by the U1+5A snRNA 107
Molecular bases of type II protein S deficiency: the I203-D204 deletion in the EGF4 domain alters GLA domain function 106
Daily and circadian rhythms of tissue factor pathway inhibitor and factor VII activity 105
Combined effect of hemostatic gene polymorphisms and the risk of myocardial infarction in patients with advanced coronary atherosclerosis 105
RNA-based therapeutic approaches for coagulation factor deficiencies 105
Factor VII mutant V154G models a zymogen-like form of factor VIIa 104
Mutation pattern in clinically asymptomatic coagulation factor VII deficiency 104
Characterization of anti-coagulant properties of prenylated coumarin ferulenol. 103
Polymorphic changes in the 5' flanking region of factor VII have a combined effect on promoter strength 102
Intracellular evaluation of ER targeting elucidates a mild form of inherited coagulation deficiency 102
Tailoring the CRISPR system to transactivate coagulation gene promoters in normal and mutated contexts 102
Cationic lipid nanosystems as carriers for nucleic acids 102
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 101
Molecular bases of CRM+ factor X deficiency: a frequent mutation (Ser334Pro) in the catalytic domain and a substitution (Glul02Lys) in the second EGF‐like domain 100
Impaired prothrombinase activity of factor X Gly381 Asp results in severe familial CRM+ FX deficiency 100
The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies 100
Attività sulla emostasi di alcune piante della medicina tradizionale indiana 98
Molecular mechanisms of FVII deficiency: expression of mutations clustered in the IVS7 donor splice site of factor VII gene. 98
Promoter methylation in coagulation F7 gene influences plasma FVII concentrations and relates to coronary artery disease. 98
An Altered Splicing Registry Explains the Differential ExSpeU1-Mediated Rescue of Splicing Mutations Causing Haemophilia A 98
Evidence for an overlapping role of clock and npas2 transcription factors in liver circadian oscillators 97
Modulation of factor VII levels by intron 7 polymorphisms: Population and in vitro studies 96
A unique exon specific U1snRNA rescues different haemophilia B - causing splicing-defective factor IX variants in mice 96
Modulation of factor V levels in plasma by polymorphisms in the C2 domain 96
Next-generation sequencing and recombinant expression characterized aberrant splicing mechanisms and provided correction strategies in factor VII deficiency 96
FXIII levels and genotypes in myocardial infarction: a potential novel prognostic biomarker? 95
Characterization of the intracellular signalling capacity of natural FXa mutants with reduced pro-coagulant activity 95
null 94
The complete impairment of factor VII gene expression by the IVS6+1g/t mutation is compatible with a severe but not lethal bleeding disorder 94
Long-chain cationic derivatives of PTA (1,3,5-triaza-7-phosphaadamantane) as new components of potential non-viral vectors 94
Replacement of the Y450 (c234) phenyl ring in the carboxyl-terminal region of coagulation factor IX causes pleiotropic effects on secretion and enzyme activity 93
null 93
Management of Kidney Transplantation in a Factor VII-Deficient Patient: Case Report 93
Gentamicin induces sub-therapeutic levels of coagulation factor VII in patients with nonsense mutations 92
Missense changes in the catalytic domain of coagulation factor X account for minimal function preventing a perinatal lethal condition 92
Contribution of factor VII genotype to activated FVII levels. Differences in genotype frequencies between northern and southern European populations. 91
The factor V Glu1608Lys mutation is recurrent in familial thrombophilia 91
Protein S mRNA in patients with protein S deficiency. 91
Detection of two missense mutations and characterization of a repeat polymorphism in the factor VII gene (F7) 90
Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect 90
Non-conventional therapeutic strategies for inherited disorders oh hemostasis 89
Exon-specific U1 snRNAs improve ELP1 exon 20 definition and rescue ELP1 protein expression in a familial dysautonomia mouse model 89
Reduced activation of the Gla19Ala FX variant via the extrinsic coagulation pathway results in symptomatic CRMred FX deficiency 88
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 88
null 87
Altered mRNA processing and FVIII biosynthesis/function as determinants of phenotype variability in the frequent Arg2016Trp Haemophilia A patients. 87
null 86
Gene therapy-based prophylaxis to rescue the "prima ballerina" 86
Activation of Endoplasmic Reticulum Stress and Unfolded Protein Response in Congenital Factor VII Deficiency 86
Disease-causing variants of the conserved+2T of 5 ' splice sites can be rescued by engineered U1snRNAs 85
Release of Tissue Factor-bearing microparticles by human dendritic cells induced by stimulation of membrane P2X7 receptors 84
null 84
In-Frame Deletion of von Willebrand Factor Exons 26-34 (D3-A3 Domains) in Type II von Willebrand Disease. 83
The somatic FAH C.1061C>A change counteracts the frequent FAH c.1062+5G>A mutation and permits U1snRNA-based splicing correction 83
null 82
Nanosistemi lipidici per la veicolazione di acidi nucleici 81
Correction of aberrant splicing causing haemophilia B through the combination of compensatory U1snRNAs and antisense oligonucleotides 81
Totale 10.832
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.313
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 460
Totale 80.773
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.091 0 133 137 506 267 475 329 369 312 331 160 72
2020/20212.796 202 160 147 290 96 242 231 330 131 454 366 147
2021/20222.248 137 262 114 73 113 104 112 106 80 187 185 775
2022/20232.359 261 184 73 301 409 315 135 179 276 15 128 83
2023/20241.269 110 140 79 45 79 210 50 77 36 48 40 355
2024/2025285 175 110 0 0 0 0 0 0 0 0 0 0
Totale 17.417